Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Cash & Equivalents (2016 - 2026)

Bioceres Crop Solutions' Cash & Equivalents history spans 11 years, with the latest figure at $14.4 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 137.4% to $14.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $14.4 million, a 137.4% increase, with the full-year FY2025 number at $32.7 million, down 26.47% from a year prior.
  • Cash & Equivalents hit $14.4 million in Q1 2026 for Bioceres Crop Solutions, down from $32.7 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for BIOX hit a ceiling of $48.1 million in Q2 2023 and a floor of -$38.5 million in Q1 2025.
  • Historically, Cash & Equivalents has averaged $22.4 million across 5 years, with a median of $33.1 million in 2025.
  • Biggest five-year swings in Cash & Equivalents: decreased 26.47% in 2025 and later surged 137.4% in 2026.
  • Tracing BIOX's Cash & Equivalents over 5 years: stood at $33.5 million in 2022, then soared by 43.78% to $48.1 million in 2023, then decreased by 7.6% to $44.5 million in 2024, then decreased by 26.47% to $32.7 million in 2025, then crashed by 55.96% to $14.4 million in 2026.
  • Business Quant data shows Cash & Equivalents for BIOX at $14.4 million in Q1 2026, $32.7 million in Q2 2025, and -$38.5 million in Q1 2025.